Welle Valuation, Funding & Investors

Welle is valued at $1.2B as of January 2024.

See full Welle profile

Last Welle valuation

$1.2B

Pre-seed · Jan 2024

Last Welle funding round

$2M

Pre-seed · Jan 2024

Cumulative funding Welle raised

$2M

across 1 funding round

Welle Overview

About Welle

Welle is a digital health company based in New York providing personalized care plans to mitigate inflammation and chronic disease risks. Its platform uses at-home testing kits for biomarkers like hsCRP and offers nutrition, supplement, and lifestyle recommendations via app-based coaching. Welle targets corporate wellness programs and partners with employers in finance and tech sectors for employee health initiatives.


Founded

2023

HQ

United StatesLos Angeles, CA

Status

Privately held

Customer focus

B2B

Revenue model

Subscription, Product sales

Valuation

$1.2B (Jan 2024)

Welle Valuation

Welle is currently valued at $1.2B, based on its pre-seed round in January 2024.

Welle valuation by funding round

Welle valuation by funding round
DateStageValuation
Jan 2024Pre-seed$1.2B

Welle Funding History

Welle has raised a total of $2M across 1 funding round.

Welle funding rounds

Welle funding rounds
DateStageRaisedValuation
Jan 2024Pre-seed$2M$1.2B

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Welle Competitors

Welle competitors include listed companies like DarioHealth and Certara, and private ones like Twin Health, Evidation Health, Cult.fit and Glooko.

Public and private companies comparable to Welle
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Twin HealthUnited StatesSan Francisco, CAPrivate--$1.4B-
Evidation HealthUnited StatesSan Francisco, CAPrivate--$1B-
Cult.fitIndiaBangalorePrivate$74M-$1.5B-
GlookoUnited StatesSan Francisco, CAPrivate--$476M-
DarioHealthUnited StatesUnited StatesPublicly listed$22M($36M)$69M4.0x
CertaraUnited StatesUnited StatesPublicly listed$419M$103M$1.3B3.6x

Welle Public Comps

Welle is still privately-owned, but its public comps include Omada Health, Certara, Helus Pharma, Nutex Health, Indegene, JMDC, Sphere, SOPHiA Genetics, Dian Diagnostics Group and Alignment Healthcare.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Omada Health$260M($10M)3.8x3.1x(98.6x)48.5x
Certara$419M$103M3.4x3.6x13.9x12.0x
Helus Pharma-($153M)--(5.4x)(4.8x)
Nutex Health$875M$288M2.0x2.0x6.0x6.4x
Indegene$366M$68M3.7x3.3x19.9x18.2x
JMDC$324M$88M5.0x4.6x18.4x17.9x
Sphere$70M$6M14.3x6.9x156.3x103.0x
SOPHiA Genetics$77M($65M)8.8x7.5x(10.4x)(18.8x)

This data is available for Pro users. Sign up to see all Welle competitors and their valuation data.

Start Free Trial

Common questions about Welle

When was Welle founded?Welle was founded in 2023.
Where is Welle headquartered?Welle is headquartered in Los Angeles, CA, United States.
Is Welle publicly listed?No, Welle is a private company.
What is Welle's valuation?Welle was last valued at $1.2B in its pre-seed round in January 2024.
How much funding has Welle raised?Welle has raised $2M across 1 funding round.
What was Welle's last funding round?Welle's last funding round was a $2M pre-seed round in January 2024.
Which companies are comparable to Welle?Companies comparable to Welle include Twin Health, Evidation Health, Cult.fit, Glooko, DarioHealth and Certara.

See companies similar to Welle

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial